on 27 Sep 2022
Last Applicant/ Owned by
Vilnius
LT
Serial Number
79301540 filed on 18th Nov 2020
Registration Number
6854457 registered on 27th Sep 2022
Correspondent Address
JOHN ZACCARIA
Filing Basis
No Filing Basis
Disclaimer
"GENE THERAPY"
The mark consists of the wording "NORTHWAY GENE THERAPY" with the "O" in NORTHWAY being represented by the design of a DNA Helix in dark blue and orange, the rest of the wording "NORTHWAY" in dark blue, and the wording "GENE THERAPY" below in orange. The color white represents background and/or transparent areas and is not claimed as a feature of the mark. Pharmaceutical preparations, namely, forRead More
Pharmaceutical preparations, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; biological preparations for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; biological tissue cultures for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; albuminous preparations for medical purposes, namely, albumin dietary supplements; chemical preparations for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19
Scientific and technological services and research and design relating thereto, namely, research and design in the field of products and processes development of biotechnology products and processes; bacteriological research; biological research; chemistry services in the nature of product development and quality control of biotechnology products; chemical research; conducting clinical trials for others; scientific research; medical research; scientific laboratory services; technical research in the field of pharmaceutical studies; technological consultancy in the field of development of manufacturing processes for biotechnology products
No 79301540
No Service Mark
No J1379-016
No
No
No
No
No
No
No
No
26.01.29 -
Helixes
27.03.05 -
Representations of objects forming letters or numerals, including punctuation
The mark consists of the wording "NORTHWAY GENE THERAPY" with the "O" in NORTHWAY being represented by the design of a DNA Helix in dark blue and orange, the rest of the wording "NORTHWAY" in dark blue, and the wording "GENE THERAPY" below in orange. The color white represents background and/or transparent areas and is not claimed as a feature of the mark.
| Status Date | Action Taken |
|---|---|
| 07th Feb 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 18th Jan 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| 18th Jan 2023 | FINAL DISPOSITION PROCESSED |
| 27th Dec 2022 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 27th Sep 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 27th Sep 2022 | REGISTERED-PRINCIPAL REGISTER |
| 24th Aug 2022 | TTAB RELEASE CASE TO TRADEMARKS |
| 24th Aug 2022 | OPPOSITION TERMINATED NO. 999999 |
| 24th Aug 2022 | OPPOSITION DISMISSED NO. 999999 |
| 04th Jul 2022 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
